Health Wire Syria: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Syria.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on February 6, 2026

31 minutes ago

SRx Health Solutions Launches EventHorizonIQ, a Public Ledger of AI-Generated Financial Market Instability Signals

GlobeNewswire

an hour ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GlobeNewswire

an hour ago

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

GlobeNewswire

2 hours ago

Hopebridge Announces Retirement of CEO Dennis May After a Decade of Leadership

GlobeNewswire

2 hours ago

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire

2 hours ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 hours ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

GlobeNewswire

2 hours ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

GlobeNewswire

2 hours ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

GlobeNewswire

2 hours ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 hours ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 hours ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire

3 hours ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

GlobeNewswire

3 hours ago

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

GlobeNewswire

3 hours ago

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

GlobeNewswire

3 hours ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

GlobeNewswire

3 hours ago

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

GlobeNewswire

6 hours ago

HUTCHMED to Announce 2025 Final Results

GlobeNewswire

10 hours ago

Chiral raises $12M to unlock post-silicon computing beyond Moore’s Law

GlobeNewswire

13 hours ago

Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

GlobeNewswire